Business Context and Reporting Period
Company: Moderna, Inc.
Filing Type: Form 8-K (Current Report)
Date: April 16, 2020
Context: The Company entered into a material definitive agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial disclosure relates to a potential government contract award.
- Contract Value: Up to $483 million.
- Contract Duration: Approximately two-year base period; total period up to five years and six months including options.
- Use of Funds: Acceleration of mRNA-1273 vaccine development, clinical studies, and manufacturing for licensure.
Material Changes
The filing discloses the entry into the BARDA Contract on April 16, 2020. This represents a significant new revenue opportunity contingent upon the advancement of the SARS-CoV-2 vaccine candidate. No prior period financial comparisons are provided in this document.
Outlook, Risks, and Contingencies
Management Commentary: The contract is intended to fund activities to obtain licensure of mRNA-1273 through a biologics license application submission.
Risks and Contingencies:
- Termination: The government retains the right to terminate the contract at any time for its convenience.
- Payment Conditions: The $483 million figure represents a potential maximum award; actual payments depend on contract performance and terms.
- Documentation: The full contract text is not included in this filing but will be filed as an exhibit to the Form 10-Q for the period ending June 30, 2020.
Investor Verification Checklist
- Verify the specific milestones required to trigger payments under the BARDA Contract.
- Review the full contract text when filed as an exhibit to the Q2 2020 Form 10-Q.
- Monitor clinical trial progress for mRNA-1273 to assess the likelihood of contract fulfillment.
- Assess the impact of potential government termination on future revenue projections.
